Loading data for CANF — first visit, this takes a few seconds.
Can-Fite BioPharma Ltd. (CANF)
NYSE American: CANF
· Real-Time Price · USD
3.45
-0.13 (-3.63%)
At close: Aug 18, 2026, 3:52 PM
Can-Fite BioPharma Ltd. (CANF) Stock Price, Analysis & Data
-3.63% (1D)
| Bid | n/a |
| Market Cap | 7.39M |
| Revenue (ttm) | 405K |
| Net Income (ttm) | -9.83M |
| Beta | -0.04 |
| EPS (ttm) | -10.75 |
| PE Ratio (ttm) | n/a |
| Forward PE | -12.78 |
| P/B (ttm) | 0.81 |
| P/S (ttm) | 18.25 |
| Earnings Date | Mar 27, 2020 |
| Ask | n/a |
| Volume | 29,446 |
| Avg. Volume (20D) | 1,436,753 |
| Open | 3.54 |
| Previous Close | 3.58 |
| Day's Range | 3.37 - 3.56 |
| 52-Week Range | 2.56 - 13.60 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CANF
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cance...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 6, 2012
Employees 5
Stock Exchange NYSE American
Ticker Symbol CANF
Website https://www.canfite.com
Financial Performance
In 2025, Can-Fite BioPharma's revenue was 405K, a decrease of -39.91% compared to the previous year's 674K. Earnings were -9.83M, an increase of 24.72%.
Financial StatementsEarnings Surprise
Can-Fite BioPharma has released their quarterly earnings on Mar 28, 2024:
Can-Fite BioPharma Ltd. is scheduled to release its earnings on Mar 27, 2020, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2